🇺🇸 FDA
Pipeline program

AG10

AG10-201

Phase 2 small_molecule completed

Quick answer

AG10 for Familial ATTR-CM (ATTRm-CM, or FAC) is a Phase 2 program (small_molecule) at BridgeBio Oncology Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
BridgeBio Oncology Therapeutics
Indication
Familial ATTR-CM (ATTRm-CM, or FAC)
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials